Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Appl Opt ; 63(1): 17-29, 2024 Jan 01.
Artigo em Inglês | MEDLINE | ID: mdl-38175001

RESUMO

A test station setup devised to measure the emission characteristics and beam propagation parameters of a light detection and ranging (LiDAR) system is presented. The main blocks of the station to measure the accessible emission, wavelength peak and FWHM, pulse duration, pulse repetition rate, horizontal and vertical angular resolution, field of view, beam propagation factor M 2, beam waist size, waist location, and divergence are described. The performance of this test station was demonstrated using a commercial spinning LiDAR, a Velodyne VLP-16, which successfully enables these measurements for a laser beam with a wavelength of 913 nm.

2.
Acta Radiol ; 49(1): 75-9, 2008 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-18210315

RESUMO

Although imaging and clinical criteria are already established for the diagnosis of mucoid degeneration of the anterior cruciate ligament (ACL), many radiologists remain unaware of their existence. Once regarded as a rare occurrence, it has been recently suggested that its incidence is in fact very much higher than previously thought, and that it is probably underdiagnosed or misdiagnosed as partial ruptures of the ACL or as cystic ganglia. In this review, the authors revisit the literature concerning this subject and present their personal experience with it, stressing the paramount importance of magnetic resonance imaging and correlation with clinical data for a correct diagnosis.


Assuntos
Ligamento Cruzado Anterior/patologia , Artropatias/diagnóstico , Articulação do Joelho/patologia , Imageamento por Ressonância Magnética/métodos , Envelhecimento , Diagnóstico Diferencial , Cistos Glanglionares/diagnóstico , Humanos , Muco , Amplitude de Movimento Articular
3.
Rev Soc Bras Med Trop ; 33(4): 377-82, 2000.
Artigo em Inglês | MEDLINE | ID: mdl-10936952

RESUMO

One hundred and eighty-two male inbred C57/BL/6 mice were infected with 3 x 10(6) Leishmania (Leishmania) amazonensis promastigotes of the MHOM/BR/PH8 strain by means of a subcutaneous injection in the right ear. The animals were separated in three groups: 1) oral mefloquine hydrochloride treatment (16 mg/kg/day/10 days), 2) intramuscular aminosidine (Paromomycin) treatment (20 mg/kg/20 days) and 3) control. Twenty-six mice of each treated group were sacrificed, one at the end of treatment (nine weeks after inoculation), and one six weeks later (fifteen weeks after inoculation). Control Group animals were sacrificed at weeks six, nine and fifteen after inoculation. There was no significant difference between Group 1 (mefloquine) and Group 3 (control) subjects. Group 2 animals (aminosidine) presented the smallest differences of all, both at the end of the treatment and six weeks later. The histopato-logical parameters have shown the following findings: a) there was no significant difference between the mefloquine treated group and the control group; the group treated with aminosidine showed fewer of vacuolated macrophages than the control group, at week 9 (end of treatment). b) both at the end of treatment and six weeks later, evaluation of tissue necrosis and tissue fibrosis revealed no differences between the treated groups. It was found that six weeks after the end of treatment, mice in the control group presented significantly more severe degrees of fibrosis than mice in the other groups. It can be concluded that mefloquine showed limited therapeutic effect in this experimental model, whereas aminosidine had a significant effect. Nevertheless, neither of them resulted in cure of the lesions.


Assuntos
Antiprotozoários/uso terapêutico , Leishmaniose Cutânea/tratamento farmacológico , Mefloquina/uso terapêutico , Paromomicina/uso terapêutico , Animais , Avaliação Pré-Clínica de Medicamentos , Leishmania , Masculino , Camundongos , Camundongos Endogâmicos C57BL
4.
Biometals ; 12(2): 161-5, 1999 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-10406085

RESUMO

Acute or chronic zinc administration may cause hyperglycemia in experimental animals. These findings are attributed to permissive actions of glucocorticoids and glucagon upon hepatic gluconeogenesis and glycogenolysis. The effect of Zn(+)+ on plasma glucose, C-peptide, glucagon, and cortisol was investigated in healthy and insulin-dependent diabetes mellitus (IDDM) patients. Ten normal individuals (5 of each sex, aged 24.10 +/- 1.96) and 10 IDDM (5 of each sex, aged 25.20 +/- 8.10) were tested at 7:00 AM after 12-h fast. Twenty-five mg of Zn(+)+ were administered intravenously during 1 min, and blood samples were collected from the contralateral arm at 0, 3, 30, 60, 90 and 120 min after Zn(+)+ injection. The plasma levels of glucose, C-peptide, and glucagon remained constant throughout the experimental period in both groups studied. Plasma cortisol levels decreased significantly, which is consistent with our previous findings. These results suggest that, in contrast to experimental animals, acute Zn(+)+ administration, despite decreasing cortisol levels, does not change carbohydrate metabolism in human beings.


Assuntos
Diabetes Mellitus Tipo 1/metabolismo , Glucose/metabolismo , Zinco/farmacologia , Adulto , Glicemia/análise , Peptídeo C/análise , Feminino , Glucagon/sangue , Humanos , Hidrocortisona/sangue , Masculino , Zinco/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...